Corcept Therapeutics Inc (CORT) stock
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30350% above fair value
$73.71−0.82 (-1.10%)
Close on Nov 12, 2026Market cap $7.97BP/E 175.5Yield –
Corcept Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Corcept Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was 0.8%. For fiscal 2025 it was 5.9%, against 20.3% the year before. The highest annual figure on record is 36.4% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.9% | −14.4 |
| FY2024 | Dec 31, 2024 | 20.3% | −2.0 |
| FY2023 | Dec 31, 2023 | 22.2% | −5.8 |
| FY2022 | Dec 31, 2022 | 28.0% | −6.0 |
| FY2021 | Dec 31, 2021 | 34.0% | −2.2 |
| FY2020 | Dec 31, 2020 | 36.2% | −0.2 |
| FY2019 | Dec 31, 2019 | 36.4% | +0.8 |
| FY2018 | Dec 31, 2018 | 35.6% | +2.4 |
| FY2017 | Dec 31, 2017 | 33.2% | +20.7 |
| FY2016 | Dec 31, 2016 | 12.5% | +19.4 |
| FY2015 | Dec 31, 2015 | -6.8% | +97.2 |
| FY2014 | Dec 31, 2014 | -104.0% | +296.6 |
| FY2013 | Dec 31, 2013 | -400.7% | +696.2 |
| FY2012 | Dec 31, 2012 | -1096.8% | +68730.8 |
| FY2009 | Dec 31, 2009 | -69827.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 16.1% | +2.4 |
| Q1 FY2026 | Mar 31, 2026 | -30.1% | −32.3 |
| Q4 FY2025 | Dec 31, 2025 | 2.2% | −11.7 |
| Q3 FY2025 | Sep 30, 2025 | 4.9% | −20.6 |
| Q2 FY2025 | Jun 30, 2025 | 13.7% | −8.0 |
| Q1 FY2025 | Mar 31, 2025 | 2.2% | −17.9 |
| Q4 FY2024 | Dec 31, 2024 | 13.9% | −9.5 |
| Q3 FY2024 | Sep 30, 2024 | 25.5% | +0.3 |
| Q2 FY2024 | Jun 30, 2024 | 21.7% | −3.4 |
| Q1 FY2024 | Mar 31, 2024 | 20.1% | +6.0 |
| Q4 FY2023 | Dec 31, 2023 | 23.4% | +1.6 |
| Q3 FY2023 | Sep 30, 2023 | 25.2% | −6.2 |
| Q2 FY2023 | Jun 30, 2023 | 25.1% | −5.3 |
| Q1 FY2023 | Mar 31, 2023 | 14.1% | −14.5 |
| Q4 FY2022 | Dec 31, 2022 | 21.8% | −15.3 |
| Q3 FY2022 | Sep 30, 2022 | 31.4% | −6.3 |
| Q2 FY2022 | Jun 30, 2022 | 30.4% | −4.5 |
| Q1 FY2022 | Mar 31, 2022 | 28.6% | +3.9 |
| Q4 FY2021 | Dec 31, 2021 | 37.1% | +1.5 |
| Q3 FY2021 | Sep 30, 2021 | 37.7% | +9.1 |
| Q2 FY2021 | Jun 30, 2021 | 34.9% | −4.9 |
| Q1 FY2021 | Mar 31, 2021 | 24.7% | −15.7 |
| Q4 FY2020 | Dec 31, 2020 | 35.6% | −4.3 |
| Q3 FY2020 | Sep 30, 2020 | 28.6% | −11.9 |
| Q2 FY2020 | Jun 30, 2020 | 39.8% | +5.7 |
| Q1 FY2020 | Mar 31, 2020 | 40.4% | +11.2 |
| Q4 FY2019 | Dec 31, 2019 | 39.8% | +2.6 |
| Q3 FY2019 | Sep 30, 2019 | 40.5% | +4.9 |
| Q2 FY2019 | Jun 30, 2019 | 34.1% | +1.0 |
| Q1 FY2019 | Mar 31, 2019 | 29.2% | −7.2 |
| Q4 FY2018 | Dec 31, 2018 | 37.3% | −3.5 |
| Q3 FY2018 | Sep 30, 2018 | 35.6% | +3.8 |
| Q2 FY2018 | Jun 30, 2018 | 33.1% | −2.9 |
| Q1 FY2018 | Mar 31, 2018 | 36.4% | +19.2 |
| Q4 FY2017 | Dec 31, 2017 | 40.7% | +19.7 |
| Q3 FY2017 | Sep 30, 2017 | 31.9% | +17.7 |
| Q2 FY2017 | Jun 30, 2017 | 36.0% | – |
| Q1 FY2017 | Mar 31, 2017 | 17.2% | – |
| Q4 FY2016 | Dec 31, 2016 | 21.0% | – |
| Q3 FY2016 | Sep 30, 2016 | 14.1% | – |
See a number that looks wrong?